

Contains Nonbinding Recommendations

Guidance on Nilutamide

This guidance represents the Food and Drug Administration's (FDA's) current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. You can use an alternative approach if the approach satisfies the requirements of the applicable statutes and regulations. If you want to discuss an alternative approach, contact the Office of Generic Drugs.

Active ingredient: Nilutamide

Form/Route: Tablet/Oral

Recommended studies: 1 study

Type of study: Steady-State

Design: Steady state, two-way crossover or parallel *in-vivo* study

Strength: 150 mg

Subjects: Patients who are already receiving the drug at a dose of 150 mg once a day as their individual therapy and continuing on the same dose for both periods of the crossover study.

Analytes to measure (in appropriate biological fluid): Nilutamide in plasma

Bioequivalence based on (90% CI): Nilutamide

Waiver request of in-vivo testing: Not Applicable

Dissolution test method and sampling times:

Please note that a **Dissolution Methods Database** is available to the public at the OGD website at <http://www.accessdata.fda.gov/scripts/cder/dissolution/>. Please find the dissolution information for this product at this website. Please conduct comparative dissolution testing on 12 dosage units each of all strengths of the test and reference products.